Qiagen (NYSE:QGEN) Given New $48.00 Price Target at UBS Group

Qiagen (NYSE:QGEN - Free Report) had its price objective trimmed by UBS Group from $50.00 to $48.00 in a report published on Friday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other brokerages also recently issued reports on QGEN. Morgan Stanley restated an "equal weight" rating and set a $46.67 price target (down previously from $48.61) on shares of Qiagen in a report on Monday, January 6th. Jefferies Financial Group reissued a "buy" rating and set a $52.50 target price (up previously from $40.83) on shares of Qiagen in a research note on Tuesday, December 10th. HSBC lowered Qiagen from a "buy" rating to a "hold" rating and set a $47.64 price target on the stock. in a research note on Thursday, October 17th. Finally, Hsbc Global Res raised Qiagen to a "hold" rating in a research report on Thursday, October 17th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Qiagen presently has an average rating of "Hold" and an average price target of $48.78.

Qiagen Trading Down 1.5 %

Qiagen stock traded down $0.59 during trading on Friday, reaching $39.49. 509,224 shares of the company were exchanged, compared to its average volume of 1,226,139. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89. The stock's 50 day simple moving average is $43.74 and its two-hundred day simple moving average is $43.28. The company has a market capitalization of $8.76 billion, a P/E ratio of 109.93, a PEG ratio of 3.29 and a beta of 0.36. Qiagen has a 52-week low of $39.40 and a 52-week high of $49.30.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.97%. On average, equities research analysts expect that Qiagen will post 2.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC grew its stake in shares of Qiagen by 806.5% in the third quarter. GAMMA Investing LLC now owns 562 shares of the company's stock worth $26,000 after acquiring an additional 500 shares in the last quarter. Geneos Wealth Management Inc. increased its stake in shares of Qiagen by 41.5% during the fourth quarter. Geneos Wealth Management Inc. now owns 856 shares of the company's stock worth $38,000 after buying an additional 251 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Qiagen by 152.5% during the 4th quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock worth $39,000 after acquiring an additional 526 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Qiagen in the 3rd quarter valued at $53,000. Finally, Smartleaf Asset Management LLC grew its stake in shares of Qiagen by 148.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company's stock worth $63,000 after purchasing an additional 835 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company's stock.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.